Renovaro Biosciences Denmark ApS: Financial statements 2019
CVR: 26027322
Source: annual report 2019, Danish Business Authority
01/07/2018 – 30/06/2019
Renovaro Biosciences Denmark ApS (CVR 26027322) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -1,927,253 and a net result of DKK -6,845,472 compared with DKK -7,012,131 the year before. Equity in the 2019 report amounted to DKK -62,638,645. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,927,253
- Profit/Loss
- DKK -6,845,472
- Equity
- DKK -62,638,645
- Total Assets
- DKK 39,372,430
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -1.9M | -6.8M | -62.6M | 1 |
| 2018 | - | -4.5M | -7M | -55.8M | - |
| 2016 | - | -5M | -10.7M | -52M | 2 |
| 2015 | - | -17.4M | -20.4M | -41.3M | - |
| 2014 | - | -8.5M | -11.5M | -21M | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout Renovaro Biosciences Denmark ApS
Renovaro Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2001. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Enochian BioSciences Denmark ApS and DanDrit Biotech ApS. The management consists of David Hershel Weinstein. The company is owned by Lunai Bioworks Inc.. The company has 1 employee (2017). In 2026, the company reported a gross profit of DKK -4,478 and a net result of DKK -1,178,038 compared with DKK -4,629,959 the year before. Equity in the 2026 report amounted to DKK -91,933,986.
